Search Results - "SCALORI, Astrid"

Impact of P‐gp inhibition on systemic exposure of pralsetinib and dosing considerations by Suchomel, Julia, Agarwal, Priya, Anders, Doreen, Hughes, Kevin, Tang, Yang, Sane, Rucha, Scalori, Astrid, Sharma, Sunil, Cheeti, Sravanthi

“…A study to determine the impact of cyclosporine (Neoral), an inhibitor of P‐gp, on the pharmacokinetics of pralsetinib (trade name GAVRETO®) was conducted in…”
Get full text

Exploring the Impact of Hepatic Impairment on Pralsetinib Pharmacokinetics by Cheung, Kit Wun Kathy, Tang, Yang, Anders, Doreen, Barata, Teresa, Scalori, Astrid, Agarwal, Priya, Sane, Rucha, Cheeti, Sravanthi

“…Pralsetinib is a kinase inhibitor indicated for the treatment of metastatic rearranged during transfection ( ) fusion-positive non-small cell lung cancer…”
Get full text

Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies by Wedemeyer, Heiner, Forns, Xavier, Hézode, Christophe, Lee, Samuel S, Scalori, Astrid, Voulgari, Athina, Le Pogam, Sophie, Nájera, Isabel, Thommes, James A

“…Most patients with chronic hepatitis C virus (HCV) genotype 1 infection who have had a previous null response (<2-log10 reduction in HCV RNA by treatment week…”
Get full text

Hepatocellular adenoma in glycogen storage disorder type I: a clinicopathological and molecular study by Sakellariou, Stratigoula, Al-Hussaini, Hussa, Scalori, Astrid, Samyn, Marianne, Heaton, Nigel, Portmann, Bernard, Tobal, Khalid, Quaglia, Alberto

“…Sakellariou S, Al‐Hussaini H, Scalori A, Samyn M, Heaton N, Portmann B, Tobal K & Quaglia A (2012) Histopathology 60, E58–E65 Hepatocellular adenoma in…”
Get full text

Contrasting Pattern of Chronic Inflammatory Bowel Disease in Primary and Autoimmune Sclerosing Cholangitis by Bjarnason, Ingvar, Hayee, Bu, Pavlidis, Polychronis, Kvasnovsky, Charlotte, Scalori, Astrid, Sisson, Guy, Charlesworth, Annika, Shaikh, Hizbullah, Bjornsson, Einar, Heneghan, Michael A.

“…Primary sclerosing cholangitis (PSC) and autoimmune sclerosing cholangitis (AISC) are related, but distinct chronic liver diseases. PSC is associated with a…”
Get full text

Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis by Gane, Edward J., Rouzier, Régine, Hassanein, Tarek, Stedman, Catherine A., Mazur, Wlodzimierz, Kupcova, Viera, Le Pogam, Sophie, Eng, Simon, Voulgari, Athina, Morcos, Peter N., Brennan, Barbara J., Scalori, Astrid, Thommes, James

“…Background and aim Effective and safe antiviral treatment regimens are needed for patients with chronic hepatitis C (CHC) and cirrhosis. Methods An…”
Get full text

Oral contraceptives and the risk of focal nodular hyperplasia of the liver: A case-control study by Scalori, Astrid, Tavani, Alessandra, Gallus, Silvano, La Vecchia, Carlo, Colombo, Massimo

“…Objective: A role of female hormones, including oral contraceptives, has been suggested in the etiology of focal nodular hyperplasia of the liver. There is,…”
Get full text

Mo1817 – Responder Definitions for the Ulcerative Colitis Patient-Reported Outcomes Signs and Symptoms (UC-PRO/SS) Tool Using Patients with Ulcerative Colitis Treated with Etrolizumab by Higgins, Peter D., Matsui, Alison, DeBusk, Kendra, Pulley, Jennifer, Scalori, Astrid, Oh, Young S., Arulmani, Udayasankar

Get full text

Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease: Results from a Phase 1 Randomized Trial by Zhang, Wenhui, Scalori, Astrid, Fuh, Franklin, McBride, Jacqueline, She, Gaohong, Kierkus, Jaroslaw, Korczowski, Bartosz, Li, Regan, Abouhossein, Mariam, Kadva, Alysha, Park, K T, Tang, Meina Tao

Get full text

Outcome of liver disease in a large cohort of histologically proven chronic hepatitis C : Influence of HCV genotype by ROFFI, Luigi, REDAELLI, Alessandro, FORNACIARI, Giovanni, GIUSTI, Massimo, MARIN, Renato, MORALES, Rino, SANGIOVANNI, Angelo, BELLONI, Giovanni, POZZI, Massimo, POLI, Giancarla, MASCOLI, Nerina, CORRADI, Chiara, COLLOREDO, Guido, PIOLTELLI, Pietro, SCALORI, Astrid, MANCIA, Giuseppe, MINOLA, Eliseo, DONADA, Carlo, PICCIOTTO, Antonino, RIBOLI, Paolo, DEL POGGIO, Paolo, RINALDI, Gianni, PARIS, Bruno

“…To assess the influence of hepatitis C virus (HCV) genotypes on the clinical outcome of liver disease, we analysed 2,307 patients. The most frequently…”
Get full text

Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease: Results from a Phase 1 Randomized Trial by Zhang, Wenhui, Scalori, Astrid, Fuh, Franklin, McBride, Jacqueline, She, Gaohong, Kierkus, Jaroslaw, Korczowksi, Bartosz, Li, Regan, Abouhossein, Mariam, Kadva, Alysha, Park, K T, Tang, Meina Tao

“…Abstract Background Etrolizumab, a humanized anti-β7 antibody, has not been studied in children. Here, we evaluate the pharmacokinetics, pharmacodynamics, and…”
Get full text

Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study by Subbiah, Vivek, Hu, Mimi I, Mansfield, Aaron S, Taylor, Matthew H, Schuler, Martin, Zhu, Viola W, Hadoux, Julien, Curigliano, Giuseppe, Wirth, Lori, Gainor, Justin F, Alonso, Guzman, Adkins, Douglas, Godbert, Yann, Ahn, Myung-Ju, Cassier, Philippe A, Cho, Byoung Chul, Lin, Chia-Chi, Zalutskaya, Alena, Barata, Teresa, Trask, Peter, Scalori, Astrid, Bordogna, Walter, Heinzmann, Sebastian, Brose, Marcia S

“…Rearranged during transfection ( ) alterations are targetable oncogenic drivers in thyroid cancer. Primary data from the open-label, phase 1/2 ARROW study…”
Get more information

P069 Correlation Between Histologic Indices and Ulcerative Colitis Activity Measures Among Patients in the HICKORY (Etrolizumab) Open-Label Induction Cohort by Peyrin-Biroulet, Laurent, Feagan, Brian, Pai, Rish, Boruvka, Audrey, Oh, Young, Scherl, Alexis, Scalori, Astrid, Arrisi, Pablo, Tole, Swati, Rubin, David

“…BACKGROUND: Cross-sectional studies in ulcerative colitis (UC) have shown at best a moderate association between histologic and clinical measures of disease…”
Get full text

Pralsetinib in patients (pts) with advanced or metastatic RET -altered thyroid cancer (TC): Updated data from the ARROW trial by Mansfield, Aaron Scott, Subbiah, Vivek, Schuler, Martin H., Zhu, Viola Weijia, Hadoux, Julien, Brose, Marcia S., Curigliano, Giuseppe, Wirth, Lori J., Garralda, Elena, Adkins, Douglas, Godbert, Yann, Ahn, Myung-Ju, Cassier, Philippe Alexandre, Cho, Byoung Chul, Lin, Chia-Chi, Zhang, Hui, Zalutskaya, Alena, Barata, Teresa, Scalori, Astrid, Taylor, Matthew H.

“…6080 Background: Alterations in RET are targetable oncogenic drivers in TC. Pralsetinib is a highly potent, selective RET inhibitor, with demonstrated efficacy…”
Get full text

Vigorous activation of monocytes in juvenile autoimmune liver disease escapes the control of regulatory T‐cells by Longhi, Maria Serena, Mitry, Ragai R., Samyn, Marianne, Scalori, Astrid, Hussain, Munther J., Quaglia, Alberto, Mieli‐Vergani, Giorgina, Ma, Yun, Vergani, Diego

“…Interface hepatitis, the histological lesion typical of autoimmune hepatitis (AIH), is composed of CD4 and CD8 T lymphocytes and of innate immunity cells,…”
Get full text

Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin by Feld, Jordan J, Jacobson, Ira M, Jensen, Donald M, Foster, Graham R, Pol, Stanislas, Tam, Edward, Jablkowski, Maciej, Berak, Hanna, Vierling, John M, Yoshida, Eric M, Perez-Gomez, Héctor R, Scalori, Astrid, Hooper, Gregory J, Tavel, Jorge A, Navarro, Mercidita T, Shahdad, Saba, Kulkarni, Rohit, Pogam, Sophie Le, Nájera, Isabel, Eng, Simon, Lim, Chin Yin, Shulman, Nancy S, Yetzer, Ellen S

“…Graphical abstract…”
Get full text

Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies: e0145409 by Wedemeyer, Heiner, ns, Xavier, Hezode, Christophe, Lee, Samuel S, Scalori, Astrid, Voulgari, Athina, Pogam, Sophie Le, Najera, Isabel, Thommes, James A

“…Most patients with chronic hepatitis C virus (HCV) genotype 1 infection who have had a previous null response (<2-log10 reduction in HCV RNA by treatment week…”
Get full text

Risk factors for focal nodular hyperplasia of the liver: an Italian case-control study by Scalori, Astrid, Tavani, Alessandra, Gallus, Silvano, La Vecchia, Carlo, Colombo, Massimo

“…OBJECTIVES: Risk factors for focal nodular hyperplasia (FNH) of the liver are largely unknown, except for a possible role of female hormones. We evaluated the…”
Get full text

Risk factors for focal nodular hyperplasia of the liver: an Italian case-control study by Scalori, Astrid, Tavani, Alessandra, Gallus, Silvano, La Vecchia, Carlo, Colombo, Massimo

“…Risk factors for focal nodular hyperplasia (FNH) of the liver are largely unknown, except for a possible role of female hormones. We evaluated the role of…”
Get full text

HCV genotypes in Northern Italy: a survey of 1368 histologically proven chronic hepatitis C patients by Roffi, Luigi, Ricci, Alessandra, Ogliari, Cristina, Scalori, Astrid, Minola, Eliseo, Colloredo, Guido, Donada, Carlo, Ceriani, Roberto, Rinaldi, Gianni, Paris, Bruno, Fornaciari, Giovanni, Morales, Rino, Del Poggio, Paolo, Sangiovanni, Angelo, Buonocore, Marco, Bellia, Valentina, Riboli, Paolo, Nava, Maria Cristina, Panizzuti, Fabio, Piperno, Alberto, Pozzi, Massimo, Pioltelli, Pietro, Mancia, Giuseppe

“…Background/Aims: Hepatitis C virus (HCV) easily undergoes genomic changes, thus accounting for the presence of different genotypes, with different geographic…”
Get full text